ALK-positive cancer: Still a growing entity

Future Oncology

Volumn 10, Issue 2, 2014, Pages 305-321

  Gorczyński, Adam ^a   Prełowska, Monika ^b   Adam, Patrick ^c   Czapiewski, Piotr ^a   Biernat, Wojciech ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

alkoma; anaplastic large cell lymphoma; anaplastic lymphoma kinase; crizotinib; neuroblastoma; renal cell carcinoma

Indexed keywords

ENZYME ACTIVATION; HUMANS; INTRACELLULAR SPACE; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84893868482     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.184     Document Type: Review

References (135)

1. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151), 1281-1284 (1994). (Pubitemid 24107549)
2. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 174(2), 661-670 (2009).
3. Lamant L, Pulford K, Bischof D et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156(5), 1711-1721 (2000). (Pubitemid 30646709)
4. Lawrence B, Perez-Atayde A, Hibbard MK et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157(2), 377-384 (2000). (Pubitemid 30627557)
5. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14(18), 2175-2188 (1997). (Pubitemid 27248229)
6. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4), 439-449 (1997). (Pubitemid 27087107)
7. Bilsland JG, Wheeldon A, Mead A et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33(3), 685-700 (2008).
8. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89(4), 1394-1404 (1997). (Pubitemid 27080004)
9. Rohrbough J, Kent KS, Broadie K, Weiss JB. jelly belly trans-synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture. Dev. Neurobiol. 73(3), 189-208 (2013).
10. Stoica GE, Kuo A, Aigner A et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276(20), 16772-16779 (2001).
11. Stoica GE, Kuo A, Powers C et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277(39), 35990-35998 (2002).
12. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell. Biol. 18(12), 6951-6961 (1998). (Pubitemid 28533016)
13. Noh DY, Shin SH, Rhee SG. Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim. Biophys. Acta 1242(2), 99-113 (1995).
14. Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J. Biol. Chem. 285(34), 26441-26450 (2010).
15. Kinney MC, Higgins RA, Medina EA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch. Pathol. Lab. Med. 135(1), 19-43 (2011).
16. Steelman LS, Franklin RA, Abrams SL et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25(7), 1080-1094 (2011).
17. Abrams SL, Steelman LS, Shelton JG et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9(9), 1781-1791 (2010).
18. Lopiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11(1-2), 32-50 (2008).
19. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96(13), 4319-4327 (2000).
20. Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392), 1318-1321 (1998). (Pubitemid 28524494)
21. Rassidakis GZ, Feretzaki M, Atwell C et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105(2), 827-829 (2005). (Pubitemid 40070771)
22. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26(6), 813-821 (2007).
23. Singh RR, Cho-Vega JH, Davuluri Y et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 69(6), 2550-2558 (2009).
24. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol. 19(4), 341-350 (2008).
25. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18(2), 254-267 (2008). (Pubitemid 351206162)
26. Amin HM, Medeiros LJ, Ma Y et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22(35), 5399-5407 (2003). (Pubitemid 37072194)
27. Amin HM, Mcdonnell TJ, Ma Y et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23(32), 5426-5434 (2004). (Pubitemid 39044053)
28. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum. Pathol. 36(9), 939-944 (2005). (Pubitemid 41253378)
29. Qiu L, Lai R, Lin Q et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108(7), 2407-2415 (2006). (Pubitemid 44497526)
30. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 11(23), 8288-8294 (2005). (Pubitemid 41746939)
31. Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ. NPM-ALK: The prototypic member of a family of oncogenic fusion tyrosine kinases. J. Signal. Transduct. 123253 (2012).
32. Zhu H, Vishwamitra D, Curry CV et al. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26adependent mechanism. J. Pathol. 230(1), 82-94 (2013).
33. Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13(11), 1341-1348 (2007). (Pubitemid 350073594)
34. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108(8), 2796-2803 (2006).
35. Cussac D, Greenland C, Roche S et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103(4), 1464-1471 (2004). (Pubitemid 38168663)
36. Shi P, Lai R, Lin Q et al. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood 114(2), 360-370 (2009).
37. Shi B, Vishwamitra D, Granda JG, Whitton T, Shi P, Amin HM. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia 15(6), 669-683 (2013).
38. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALKinduced lymphomagenesis? Leukemia 19(7), 1128-1134 (2005). (Pubitemid 40945993)
39. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416(2), 153-159 (2008).
40. Wang YW, Tu PH, Lin KT, Lin SC, Ko JY, Jou YS. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia 13(8), 704-715 (2011).
41. Vishwamitra D, Li Y, Wilson D et al. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am. J. Pathol. 180(5), 1772-1780 (2012).
42. Bonvini P, Dalla Rosa H, Vignes N, Rosolen A. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylaminodemethoxygeldanamycin: role of the cochaperone carboxyl heat shock protein 70-interacting protein. Cancer Res. 64(9), 3256-3264 (2004). (Pubitemid 38581430)
43. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71(13), 4403-4411 (2011).
44. Coco S, De Mariano M, Valdora F et al. Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. J. Hum. Genet. 57(10), 682-684 (2012).
45. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4), 848-858 (1985). (Pubitemid 15242469)
46. Kaneko Y, Frizzera G, Edamura S et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73(3), 806-813 (1989). (Pubitemid 19069189)
47. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93(9), 3088-3095 (1999). (Pubitemid 29200802)
48. Meech SJ, Mcgavran L, Odom LF et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 98(4), 1209-1216 (2001).
49. Hernandez L, Bea S, Bellosillo B et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol. 160(4), 1487-1494 (2002). (Pubitemid 34411651)
50. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 156(3), 781-789 (2000). (Pubitemid 30626935)
51. Touriol C, Greenland C, Lamant L et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95(10), 3204-3207 (2000). (Pubitemid 30321174)
52. Tort F, Pinyol M, Pulford K et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest. 81(3), 419-426 (2001). (Pubitemid 32245073)
53. Cools J, Wlodarska I, Somers R et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34(4), 354-362 (2002). (Pubitemid 34787456)
54. Lamant L, Gascoyne RD, Duplantier MM et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37(4), 427-432 (2003). (Pubitemid 36775787)
55. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93(8), 2697-2706 (1999). (Pubitemid 29181203)
56. Delsol G, Jaffe ES, Falini B. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Swerdlow S, Campo E, Harris NL (Eds). IARC, Lyon, France, 312-316 (2008).
57. Mason D, Harris NL, Delsol G. Anaplastic large cell lymphoma, ALK-negative. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Swerdlow S, Campo E, Harris NL (Eds). IARC, Lyon, France, 317-319 (2008).
58. Lamant L, De Reynies A, Duplantier MM et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109(5), 2156-2164 (2007). (Pubitemid 46348218)
59. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26(25), 4124-4130 (2008).
60. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11), 3913-3921 (1999). (Pubitemid 29249840)
61. Savage KJ, Harris NL, Vose JM et al. ALKanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12), 5496-5504 (2008).
62. Yu R, Chen G, Zhou C et al. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas. Leuk. Res. 36(9), 1141-1146 (2012).
63. Ten Berge RL, Meijer CJ, Dukers DF et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99(12), 4540-4546 (2002). (Pubitemid 34627225)
64. Mosse YP, Lim MS, Voss SD et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group Phase 1 consortium study. Lancet Oncol. 14(6), 472-480 (2013).
65. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364(8), 775-776 (2011).
66. Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J. 18(5), 450-456 (2012).
67. Delsol G, Campo E, Gascoyne R. ALKpositive large B-cell lymphoma. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Swerdlow S, Campo E, Harris NL (Eds). IARC, Lyon, France, 244-245 (2008).
68. De Paepe P, Baens M, Van Krieken H et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102(7), 2638-2641 (2003). (Pubitemid 37193606)
69. Onciu M, Behm FG, Downing JR et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 102(7), 2642-2644 (2003). (Pubitemid 37193607)
70. Van Roosbroeck K, Cools J, Dierickx D et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95(3), 509-513 (2010).
71. Takeuchi K, Soda M, Togashi Y et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 96(3), 464-467 (2011).
72. Lee HW, Kim K, Kim W, Ko YH. ALKpositive diffuse large B-cell lymphoma: report of three cases. Hematol. Oncol. 26(2), 108-113 (2008). (Pubitemid 351951340)
73. Beltran B, Castillo J, Salas R et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J. Hematol. Oncol. 2, 11 (2009).
74. Morgan EA, Nascimento AF. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv. Hematol. 2012, 529572 (2012).
75. Ott G, Ziepert M, Klapper W et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116(23), 4916-4925 (2010).
76. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000). (Pubitemid 30082188)
77. Cerchietti L, Damm-Welk C, Vater I et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One 6(4), e18436 (2011).
78. Galkin AV, Melnick JS, Kim S et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl Acad. Sci. USA 104(1), 270-275 (2007). (Pubitemid 46068021)
79. Janik JS, Janik JP, Lovell MA, Hendrickson RJ, Bensard DD, Greffe BS. Recurrent inflammatory pseudotumors in children. J. Pediatr. Surg. 38(10), 1491-1495 (2003). (Pubitemid 37238792)
80. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 31(4), 509-520 (2007). (Pubitemid 46569034)
81. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod. Pathol. 14(6), 569-576 (2001). (Pubitemid 32554081)
82. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59(12), 2776-2780 (1999). (Pubitemid 29283106)
83. Cook JR, Dehner LP, Collins MH et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am. J. Surg. Pathol. 25(11), 1364-1371 (2001). (Pubitemid 33022051)
84. Bridge JA, Kanamori M, Ma Z et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159(2), 411-415 (2001). (Pubitemid 32751070)
85. Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38(2), 187-190 (2003). (Pubitemid 37093436)
86. Ma Z, Hill DA, Collins MH et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37(1), 98-105 (2003). (Pubitemid 36417927)
87. Takeuchi K, Soda M, Togashi Y et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin. Cancer Res. 17(10), 3341-3348 (2011).
88. Panagopoulos I, Nilsson T, Domanski HA et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer. 118(5), 1181-1186 (2006). (Pubitemid 43185605)
89. Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr. Blood Cancer 45(6), 796-801 (2005). (Pubitemid 41416489)
90. Fuehrer NE, Keeney GL, Ketterling RP, Knudson RA, Bell DA. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. Arch. Pathol. Lab. Med. 136(6), 623-626 (2012).
91. Butrynski JE, D'adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010).
92. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
93. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007). (Pubitemid 47206930)
94. Lin E, Li L, Guan Y et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res. 7(9), 1466-1476 (2009).
95. Takahashi T, Sonobe M, Kobayashi M et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann. Surg. Oncol. 17(3), 889-897 (2010).
96. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247-4253 (2009).
97. Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol. Cancer 9, 188 (2010).
98. Penzel R, Schirmacher P, Warth A. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J. Thorac. Oncol. 7(7), 1198-1199 (2012).
99. Takeuchi K, Choi YL, Togashi Y et al. KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15(9), 3143-3149 (2009).
100. Jung Y, Kim P, Keum J et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 51(6), 590-597 (2012).
101. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 7(2), e31323 (2012).
102. Jokoji R, Yamasaki T, Minami S et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J. Clin. Pathol. 63(12), 1066-1070 (2010).
103. Yoshida A, Tsuta K, Nakamura H et al. Comprehensive histologic analysis of ALKrearranged lung carcinomas. Am. J. Surg. Pathol. 35(8), 1226-1234 (2011).
104. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15(16), 5216-5223 (2009).
105. Mano H, Takeuchi K. EML4-ALK fusion in lung. Am. J. Pathol. 176(3), 1552-1553; author reply 1553-1554 (2010).
106. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
107. Hallberg B, Palmer RH. ALK and NSCLC: targeted therapy with ALK inhibitors. F1000 Med. Rep. 3, 21 (2011).
108. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004-1012 (2011).
109. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 108(18), 7535-7540 (2011).
110. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res. 18(17), 4682-4690 (2012).
111. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 369(9579), 2106-2120 (2007). (Pubitemid 46935947)
112. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167(1), 213-222 (2005). (Pubitemid 40884782)
113. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215), 967-970 (2008).
114. Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215), 930-935 (2008).
115. De Brouwer S, De Preter K, Kumps C et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16(17), 4353-4362 (2010).
116. Schönherr C, Ruuth K, Kamaraj S et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31(50), 5193-5200 (2012).
117. Berry T, Luther W, Bhatnagar N et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22(1), 117-130 (2012).
118. Martinsson T, Eriksson T, Abrahamsson J et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 71(1), 98-105 (2011).
119. Chand D, Yamazaki Y, Ruuth K et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis. Model. Mech. 6(2), 373-382 (2013).
120. Bresler SC, Wood AC, Haglund EA et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3(108), 108ra114 (2011).
121. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin. Cancer Res. 18(10), 2740-2753 (2012).
122. Debelenko LV, Raimondi SC, Daw N et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod. Pathol. 24(3), 430-442 (2011).
123. Marino-Enriquez A, Ou WB, Weldon CB, Fletcher JA, Perez-Atayde AR. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 50(3), 146-153 (2011).
124. Sugawara E, Togashi Y, Kuroda N et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118(18), 4427-4436 (2012).
125. Sukov WR, Hodge JC, Lohse CM et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod. Pathol. 25(11), 1516-1525 (2012).
126. Du XL, Hu H, Lin DC et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. (Berl.) 85(8), 863-875 (2007). (Pubitemid 47077107)
127. Jazii FR, Najafi Z, Malekzadeh R et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J. Gastroenterol. 12(44), 7104-7112 (2006). (Pubitemid 44890638)
128. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 358(2), 399-403 (2007). (Pubitemid 46755722)
129. Tuma RS. ALK gene amplified in most inflammatory breast cancers. J. Natl Cancer Inst. 104(2), 87-88 (2012).
130. Powers C, Aigner A, Stoica GE, Mcdonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277(16), 14153-14158 (2002). (Pubitemid 34968027)
131. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 11(2), 145-156 (2009).
132. Stylianou DC, Auf Der Maur A, Kodack DP et al. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28(37), 3296-3306 (2009).
133. Li XQ, Hisaoka M, Shi DR, Zhu XZ, Hashimoto H. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum. Pathol. 35(6), 711-721 (2004). (Pubitemid 38881081)
134. Dirks WG, Fahnrich S, Lis Y, Becker E, Macleod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100(1), 49-56 (2002). (Pubitemid 34602064)
135. Filtenborg-Barnkob BE, Bzorek M. Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. Hum. Pathol. 44(8), 1656-1664 (2013)